How much funding has AER Therapeutics raised?

AER Therapeutics has raised $36.0M in total funding, most recently a Series A round.

Where is AER Therapeutics headquartered?

AER Therapeutics is headquartered in Research Triangle Park.

What industry is AER Therapeutics in?

AER Therapeutics operates in Biotech, Healthcare.

AER Therapeutics

Q: Who are AER Therapeutics's investors?

AER Therapeutics's investors include OrbiMed, Hatteras Venture Partners, Canaan Partners.

Targeting Mucus to Improve Lung Health

Research Triangle Park · $36.0M raised

Biotech

Healthcare

Headquarters: Research Triangle Park
Business Model: B2B
Website: aertherapeutics.com

Total Funding: $36.0M
Last Round: $36.0M Series AApr 2023
Rounds: 1

About

Aer Therapeutics is a clinical-stage biopharmaceutical company developing a therapeutic solution for muco-obstructive lung diseases such as COPD and asthma. Its lead program, AER-01, is a mucolytic candidate in Phase 2 clinical trials targeting mucus plugs, with a mission to help patients breathe easier and transform respiratory care. The company is headquartered in Research Triangle Park, North Carolina, and closed a $36 million Series A financing to advance AER-01's development.

Summary

AER Therapeutics is a Biotech company based in Research Triangle Park. It has raised $36.0M in total across 1 round, most recently a $36.0M Series A round in Apr 2023. Investors include OrbiMed, Hatteras Venture Partners and Canaan Partners.